Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.

Abstract

The hypomethylating agents decitabine and azacitidine have been found to improve the outcome of patients with myelodysplastic syndrome (MDS); however, the clinical choice between them is controversial. Therefore, this meta-analysis was performed to compare the efficacy, toxicity, and survival advantage of decitabine and azacitidine in patients with MDS. Eleven trials with a total of 1392 patients with MDS (decitabine, n = 768; azacitidine, n = 624) were included for analysis. The pooled estimates of partial response, hematologic improvement, and overall response rates for azacitidine were significantly higher than for decitabine. There were no differences between these 2 drugs regarding complete response, red blood cell transfusion-independent rates, and grade 3 or 4 hematologic toxicity. When compared with best supportive care, azacitidine significantly improved overall survival (hazard ratio [HR], 0.69; 95% CI, 0.54-0.87) and time to acute myeloid leukemia transformation (HR, 0.51; 95% CI, 0.35-0.74). But these benefits were not found with decitabine. Among patients with higher risk (International Prognostic Scoring System value of 3) or older than 75 years, treatment with azacitidine was a favorable factor, whereas decitabine showed no advantage. Therefore, with higher overall response rates and better survival benefits, azacitidine is recommended as the first-line hypomethylating agent for MDS, especially in elderly patients or those with high risk.

• Authors: Mixue Xie, Qi Jiang, Yanhui Xie
• Journal: Clinical lymphoma, myeloma & leukemia (Clin Lymphoma Myeloma Leuk) Vol. 15 Issue 1 Pg. 22-8 (Jan 2015) ISSN: 2152-2669 [Electronic] United States
• PMID: 25042977 (Publication Type: Journal Article, Meta-Analysis, Review)
• Copyright: Copyright © 2015 Elsevier Inc. All rights reserved.

Chemical References

• Antimetabolites, Antineoplastic
• Decitabine
• Azacitidine

Topics

• Antimetabolites, Antineoplastic (administration & dosage, adverse effects, therapeutic use)
• Azacitidine (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
• Comparative Effectiveness Research
• Decitabine
• Humans
• Myelodysplastic Syndromes (drug therapy, mortality)
• Publication Bias
• Treatment Outcome